open access

Ahead of print
Original articles
Published online: 2020-04-22
Get Citation

Influence of lipid profile and statin administration on arterial stiffness in renal transplant recipients

Zbigniew T. Heleniak, Sarah Illersperger, Susanne Brakemeier, Alicja Dębska-Ślizień, Paul Bach, Klemens Budde, Fabian Halleck
DOI: 10.5603/CJ.a2020.0063
·
Pubmed: 32329037

open access

Ahead of print
Original articles
Published online: 2020-04-22

Abstract

Background: Hyperlipidemia is one of the major risk factors for developing a cardiovascular disease (CVD) and it is a frequent post-transplant complication, occurring in up to 60% of the renal transplant recipients (RTRs). Lipid lowering therapy with HMG-CoA reductase inhibitors (statins) is generally recommended and may reduce the overall cardiovascular risk. The aim of this study was to evaluate the lipid profile, statin administration and their relationship with arterial stiffness parameters in renal transplant recipients.

Methods: Three hundred and forty-four stable RTRs (62.5% male) transplanted between 1994 and 2018 were randomly enrolled to the study. The following parameters of arterial stiffness was measured in each patient: carotid femoral pulse wave velocity (baPWV left and right, cfPWV) and pulse pressure (PP right and left). The study group was divided based on the use statins: 143 (41.6%) and 201 (58.4%). RTRs were qualified to the statin (+) and the statin (–) group, respectively.

Results: In the statin (+) as compared to statin (–) group there were more patients with a CVD (32.9% vs. 14.9%) and diabetes (25.2% vs. 14.4%). In the whole study group, CVD was associated with a significant increase of both baPWV and cfPWV as well as PP (8.5 mmHg). There were significant differences in arterial stiffness parameters (baPWV, cfPWV, PP) between the statin (+) and the statin (–) group.

Conclusions: Arterial stiffness was increased in RTRs with CVD and hyperlipidemia. The control of hyperlipidemia was poor in RTRs.

Abstract

Background: Hyperlipidemia is one of the major risk factors for developing a cardiovascular disease (CVD) and it is a frequent post-transplant complication, occurring in up to 60% of the renal transplant recipients (RTRs). Lipid lowering therapy with HMG-CoA reductase inhibitors (statins) is generally recommended and may reduce the overall cardiovascular risk. The aim of this study was to evaluate the lipid profile, statin administration and their relationship with arterial stiffness parameters in renal transplant recipients.

Methods: Three hundred and forty-four stable RTRs (62.5% male) transplanted between 1994 and 2018 were randomly enrolled to the study. The following parameters of arterial stiffness was measured in each patient: carotid femoral pulse wave velocity (baPWV left and right, cfPWV) and pulse pressure (PP right and left). The study group was divided based on the use statins: 143 (41.6%) and 201 (58.4%). RTRs were qualified to the statin (+) and the statin (–) group, respectively.

Results: In the statin (+) as compared to statin (–) group there were more patients with a CVD (32.9% vs. 14.9%) and diabetes (25.2% vs. 14.4%). In the whole study group, CVD was associated with a significant increase of both baPWV and cfPWV as well as PP (8.5 mmHg). There were significant differences in arterial stiffness parameters (baPWV, cfPWV, PP) between the statin (+) and the statin (–) group.

Conclusions: Arterial stiffness was increased in RTRs with CVD and hyperlipidemia. The control of hyperlipidemia was poor in RTRs.

Get Citation

Keywords

arterial stiffness, kidney transplantation, statin, hyperlipidemia

About this article
Title

Influence of lipid profile and statin administration on arterial stiffness in renal transplant recipients

Journal

Cardiology Journal

Issue

Ahead of print

Published online

2020-04-22

DOI

10.5603/CJ.a2020.0063

Pubmed

32329037

Keywords

arterial stiffness
kidney transplantation
statin
hyperlipidemia

Authors

Zbigniew T. Heleniak
Sarah Illersperger
Susanne Brakemeier
Alicja Dębska-Ślizień
Paul Bach
Klemens Budde
Fabian Halleck

References (26)
  1. Robertsen I, Asberg A, Granseth T, et al. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. Transplantation. 2014; 97(12): 1266–1271.
  2. Mason J, Kleemann F, Bankart J, et al. Blood pressure in renal transplant recipients: are there independent predictors for achieving target blood pressure? Nephron Clin Pract. 2009; 111(3): c159–c166.
  3. Hjelmesaeth J, Hartmann A, Midtvedt K, et al. Metabolic cardiovascular syndrome after renal transplantation. Nephrol Dial Transplant. 2001; 16(5): 1047–1052.
  4. Pannu HS, Singh D, Sandhu JS. Lipid profile before and after renal transplantation. A longitudinal study. Ren Fail. 2003; 25(3): 411–417.
  5. Jardine AG, Gaston RS, Fellstrom BC, et al. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011; 378(9800): 1419–1427.
  6. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158(11): 825–830.
  7. Saran M, Czyżewski Ł, Wyzgał J, et al. Comparative Analysis of Arterial Stiffness and Body Composition in Early and Late Periods After Kidney Transplantation. Transplant Proc. 2018; 50(6): 1829–1833.
  8. Boutouyrie P, Fliser D, Goldsmith D, et al. Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrol Dial Transplant. 2014; 29(2): 232–239.
  9. Holdaas H, de Fijter JW, Cruzado JM, et al. ELEVATE Study Group. Cardiovascular parameters to 2 years after kidney transplantation following early switch to everolimus without calcineurin inhibitor therapy: an analysis of the randomized ELEVATE study. Transplantation. 2017; 101(10): 2612–2620.
  10. D'elia L, La Fata E, Iannuzzi A, et al. Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2018; 40(7): 601–608.
  11. Laurent S, Cockcroft J, Van Bortel L, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27(21): 2588–2605.
  12. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension. 2004; 44(2): 186–190.
  13. Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011; 22(7): 1335–1341.
  14. Waters DD. LDL-cholesterol lowering and renal outcomes. Curr Opin Lipidol. 2015; 26(3): 195–199.
  15. Kasiske BL. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant. 2005; 5(6): 1576.
  16. Kasiske BL, Heim-Duthoy KL, Singer GG, et al. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation. 2001; 72(2): 223–227.
  17. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2014(1): CD005019.
  18. Tuncer M, Süleymanlar G, Ersoy FF, et al. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplant Proc. 2000; 32(3): 622–625.
  19. Cravedi P, Perico N, Remuzzi G. Non-immune interventions to protect kidney allografts in the long term. Kidney Int Suppl. 2010(119): S71–S75.
  20. Cosio FG, Pesavento TE, Pelletier RP, et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis. 2002; 40(3): 638–643.
  21. Grigoropoulou P, Tentolouris A, Eleftheriadou I, et al. Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia. Diab Vasc Dis Res. 2019; 16(1): 38–46.
  22. Korogiannou M, Xagas E, Marinaki S, et al. Arterial stiffness in patients with renal transplantation; associations with co-morbid conditions, evolution, and prognostic importance for cardiovascular and renal outcomes. Front Cardiovasc Med. 2019; 6: 67.
  23. O’Rourke M, O’Brien C, Weber T. Arterial Stiffness, Wave Reflection, Wave Amplification: Basic Concepts, Principles of Measurement and Analysis in Humans. Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases. 2014: 3–13.
  24. Theilade S, Claggett B, Hansen TW, et al. TREAT investigators. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). J Hum Hypertens. 2016; 30(1): 46–52.
  25. Delahousse M, Chaignon M, Mesnard L, et al. Aortic stiffness of kidney transplant recipients correlates with donor age. J Am Soc Nephrol. 2008; 19(4): 798–805.
  26. Navarro-Muñoz M, Bonet J, Bayés B, et al. Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation? Transplant Proc. 2007; 39(7): 2259–2263.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl